Skip to main content

Advertisement

Table 1 Confirmed cytokine protection hits from the NCC library screen

From: Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions

Drug class Compound AB screening (% quetiapine) AB EC50 (μM) MBP EC50 (μM) Hit in OL diffa
SERM Raloxifene 92 0.03 0.05
Toremifene 73 0.02 0.01
Tamoxifen 117 0.02 0.01
Mestranol 93 0.92 0.79  
Clomiphene 52 0.01 0.01  
Tricyclic anti-depressants Perphenazine 96 0.01 0.03
Fluphenazine 91 0.02 0.02
Prochlorperazine 110 0.04 0.04
Trifluoperazine 155 0.02 0.03
Quetiapine 130 0.15 0.13
Non-tricyclic anti-depressants Perospirone 85 0.22 0.15
Bupropion 71 3.89 3.86
Bifemelane 78 0.20 0.26  
Cinanserin 64 0.97 1.59  
Trazadone 55 7.18 5.42  
Muscarinic Clemastinec   0.14 0.14
Benztropine 123 0.17 0.14
Donepezil 95 0.46 0.74
Vesamicol 151 1.83 2.26
Oxybutynin 92 0.67 0.54
Propantheline 91 2.95 1.25  
Adrenergic Salmeterol 55 0.22 0.20
Betaxolol 52 5.56 6.21
Ion channel Ifenprodil 162 0.36 0.52
Benproperine 99 0.43 0.12
Proxymetacaine 98 1.23 0.78
DMPP 54 2.18 2.84
Anti-fungal Bifonazole 105 0.44 b
Clotrimazole 171 0.77 b  
Econazole 90 0.34 b  
Antidiabetic Pioglitazone 56 7.34 b  
LO inhibitor MK886 51 0.31 0.19  
Histamine H1 Antagonists Hydroxyzine Pamoate 106 0.15 0.11  
Meclizine 97 0.12 0.10  
Retinoids All-trans-retinoic acid 128 0.88 0.44  
Acitretin 69 2.23 1.09  
  1. LO lipooxygenase
  2. aHit in acute OL differentiation assay (as determined in [15])
  3. bInconsistent, weak OL differentiation activity
  4. cNot in NCC library